


Data Sheet

Product Information

Catalog Number	BP22560
Product Name	Barasertib-HQPA
Description	Barasertib-HQPA (AZD2811) is a highly selective Aurora B inhibitor with an IC ₅₀ of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells.
Targets&IC ₅₀	Aurora B: 0.37 nM (IC ₅₀);
In vitro	Barasertib-HQPA (3 μM, 3 hours) significantly decreases expression of the phosphorylated forms of histone H3 in freshly isolated leukemia cells. Barasertib-hydroxyquinazoline pyrazol anilide (HQPA)] is converted rapidly to the active Barasertib-HQPA in plasma. Barasertib-HQPA treatment induced defective cell survival, polyploidy, and cell death in LNCaP cell line. Barasertib-HQPA induces a marked anti-proliferative effect accompanied by the appearance of a polyploid population, which in most cases led to apoptosis.
In vivo	Barasertib (AZD1152, 25 mg/kg) markedly suppresses the growth and weights of AZD1152-treated tumors. Barasertib (AZD1152, 5 mg/kg) enhances the ability of vincristine or daunorubicin to inhibit the proliferation of human MOLM13 leukemic xenografts. Barasertib (AZD1152, (10-150 mg/kg/d) potently inhibited the growth of human colon, lung, and hematologic tumor xenografts (mean tumor growth inhibition range, 55% to 100%; P < 0.05) in immunodeficient mice.
CAS No.	722544-51-6
Chemical Formula	C ₂₆ H ₃₀ FN ₇ O ₃
Molecular Weight	507.56

Solubility	DMSO: ≥ 22 mg/mL (43.34 mM)
Storage	Powder: -20°C for 2 years In solvent: -80°C for 1 year
Chemical Structure OR Tested Image	

Purdue Bioscience Inc.

750 50th St, Brooklyn, NY 11220, USA

<https://www.purduebio.com>

1-877.618.7311

info@purduebio.com

v2 Revision on 12/28/2022